Journal profile · Immunology

Human Immunology

ISSN 0198-8859 · eISSN 1879-1166 · Elsevier Inc. · UNITED STATES · Monthly · Founded 1980

Human Immunology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.06; hybrid open access; APC about USD 3,600; median 90 days to acceptance (109 articles, last 24 months); community-reported acceptance: about 50%; 342 articles in 2025; indexed in SCIE and Scopus.

Impact factor2.06Latest value listed by LetPub
CAS zoneZone 4 · Medicine2025 upgraded edition, major category · 2026 Xinrui edition Zone 4 · Medicine
Review time90 daysMedian, submission to acceptance · 109 articles, last 24 months · PubMed
APCUSD 3,600Hybrid journal: charged only for open-access articles
Acceptanceabout 50%Community average
Articles per year3422025 · OpenAlex count

Scope

Aims, scope and focus

Human Immunology is published by Elsevier Inc. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are T-cell and B-cell Immunology, Immune Cell Function and Interaction and Renal Transplantation Outcomes and Treatments, together about 44.7% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)

Human Immunology publishes full-length, original, hypothesis-driven basic and clinical research articles as well as brief communications, reviews and editorials covering immunogenetics, transplantation immunology, autoimmunity, and immunity to infectious diseases in humans. It also publishes short population reports, which are tied to the allelefrequencies.net database, describing allele frequencies of HLA and KIR.The journal's scope includes understanding the genetic and functional mechanisms that distinguish human individuals in their immune responses to allografts, pregnancy, infections or vaccines as well as the immune responses that lead to autoimmunity, allergy or drug hypersensitivity. It also includes examining the distribution of the genes controlling these responses in populations.Research areas include: • Studies of the genetics, genomics, polymorphism, evolution, and population distribution of immune-related genes • Studies of the expression, structure and function of the products of immune-related genes • Immunogenetics of susceptibility to infectious and autoimmune disease, and allergy • The role of the immune-related genes in hematopoietic stem cell, solid organ, and vascularized composite allograft transplant • Histocompatibility studies including alloantibodies, epitope definition, and T cell alloreactivity • Studies of immunologic tolerance and pregnancy • T cell, B cell, NK and regulatory cell functions, particularly related to subjects within the journal's scope • Pharmacogenomics and vaccine development in the context of immune-related genesHuman Immunology considers immune-related genes to include those encoding classical and non-classical HLA, KIR, MIC, minor histocompatibility antigens (mHAg), immunoglobulins, TCR, BCR, proteins involved in antigen processing and presentation, complement, Fc receptors, chemokines and cytokines. Other immune-related genes may be considered.Human Immunology is also interested in bioinformatics of immune-related genes and organizational topics impacting laboratory processes, organ allocation, clinical strategies, and registries related to autoimmunity and transplantation.Original papers with new data will be given preference over uninvited reviews and meta-analyses.Original papers with new data will be given preference over uninvited reviews and meta-analyses. As the flagship scientific publication of the American Society for Histocompatibility and Immunogenetics (ASHI), Human Immunology is primarily d

From the journal's Aims & Scope

Research area (LetPub): Immunology

Main research topics OpenAlex counts of recent articles; shares are approximate

  1. T-cell and B-cell ImmunologyImmunology and Microbiology20.6%
  2. Immune Cell Function and InteractionImmunology and Microbiology15.4%
  3. Renal Transplantation Outcomes and TreatmentsMedicine8.7%
  4. Immunotherapy and Immune ResponsesImmunology and Microbiology8.5%
  5. Monoclonal and Polyclonal Antibodies ResearchMedicine5.4%
  6. Cytomegalovirus and herpesvirus researchMedicine4%
  7. Immunodeficiency and Autoimmune DisordersImmunology and Microbiology3.9%
  8. Transplantation: Methods and OutcomesMedicine3.6%

Rankings & indexing

CAS ranking and database indexing

CAS Journal Ranking

CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
LevelCategoryZone
MajorMedicineZone 4
MinorImmunologyZone 4

Top journal: noReview journal: no

CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
LevelCategoryZone
MajorMedicineZone 4
MinorImmunologyZone 4

Top journal: noReview journal: not marked

CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
LevelCategoryZone
MajorMedicineZone 4
MinorImmunologyZone 4

Top journal: noReview journal: no

Database indexing

SCIEScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Metrics

Impact metrics and publication volume

Impact

Impact factor
2.06LetPub ·
Impact factor (publisher)
2.1Publisher website ·
CiteScore 2026-06
3.7LetPub ·
CiteScore (publisher)
3.7Publisher website ·
SJR 2026-06
0.62LetPub ·
SNIP 2026-06
0.6LetPub ·
h-index
87LetPub ·
h-index
128OpenAlex ·
i10-index
4,020OpenAlex ·
2-year mean citedness
1.08OpenAlex ·
Self-citation rate
9.5%LetPub ·
Share of gold OA articles
18.18%LetPub ·

Volume

Articles per year
133LetPub ·

Articles by year OpenAlex count · 16,210 in total · the current year is incomplete

YearArticlesOpen accessCitations
20261336029
202534259235
202436657645
202325832442
202210137941
2021125463,082

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Review & acceptance

Review time and acceptance

Review time from article dates manuscript dates registered with PubMed · to

90 daysMedian, submission to acceptance · P25–P75 59 days – 122 days

Acceptance to online
median 8 days (109 articles)
Submission to online
median 97 days
Sample
109 articles with submission and acceptance dates (338 in the window); the latest was accepted on

Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".

Other sources

Average review time (community reports)
about 1.5 monthsLetPub ·
Average acceptance (community reports)
50%LetPub ·
Submission to first decision
1 daysPublisher website ·
First decision after review
35 daysPublisher website ·
Submission to acceptance
109 daysPublisher website ·
Acceptance to publication
10 daysPublisher website ·

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

Fees & open access

APC and open-access policy

Hybrid open accessLetPub

A subscription journal in which authors can pay to publish their article open access.

SourceAPCFee waiverLicenseObserved
OpenAlexUSD 3,600 / EUR 3,370 / GBP 2,880 / JPY 446,510——
Publisher websiteUSD 3,800——

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Submission

Article types and submission policies (journal website)

Policy excerpts from the journal's websiteOpen access
Open access Open Access

Article Publishing Charge (APC): USD 3,800 (excluding taxes). The amount you pay may be reduced during submission if applicable.Review this journal’s open access policy.

Source ↗Publisher website ·

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Profile

Publication details and official links

Publisher
Elsevier Inc.
Country or region
UNITED STATES
Language
English
Frequency
Monthly
Founded
1980
ISSN
0198-8859
Electronic ISSN
1879-1166
Official links

FAQ

Frequently asked questions about Human Immunology

What CAS zone is Human Immunology in?

In the 2025 upgraded edition of the CAS Journal Ranking, Human Immunology is in Zone 4 of Medicine, and in Zone 4 of the minor category Immunology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.

What is the impact factor of Human Immunology?

The latest impact factor listed by LetPub is 2.06; CiteScore 3.7, h-index 128.

How long does peer review take at Human Immunology?

Based on the dates recorded on 109 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 90 days (interquartile range 59–122 days); authors report an average review time of about 1.5 months; the community-reported acceptance is “about 50%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.

Which databases index Human Immunology?

According to LetPub and DOAJ records, Human Immunology is indexed in SCIE and Scopus.

Is Human Immunology open access, and what is the APC?

Human Immunology is a hybrid journal. For open-access publication: APC about USD 3,600.

Sources and updates

The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .